65,437 trials
Bioequivalence
Primary: Cmax of Norethindrone — 10.94; 10.00 ng/mL
Influenza
Primary: Antibody Responses After the First and Second Vaccinations — 19; 9; 15; 19 Percentages of Subjects
Alzheimer's Disease
Primary: Change From Baseline in the Alzheimer's Disease Assessment Scale - Japan Cognitive Subscale (ADAS-J Cog) — 24.8; 25.2; 25.0; 26.1 units on a scale
Crohn's Disease
Primary: Occurrence of at Least One Treatment-emergent Adverse Event During This Study (Maximum 122 Weeks) — 12; 15; 32; 30 subjects
Hypertension
Primary: Change From Baseline in Mean Seated Trough Cuff Systolic Blood Pressure (SBP) to Week 7 — -28.5; -37.0 mmHg — p=<0.0001
Prostate Cancer · Metastatic · Hormone Refractory
Primary: Prostate Specific Antigen (PSA) Response — 17; 29 Participants
Thyroid Cancer
Primary: Objective Response Rate — 6 Participants
Colorectal Cancer
Primary: Number of Patients With an Objective Disease Progression Event — 20; 24; 24 Participants
Non Small Cell Lung Cancer
Primary: Progression-Free Survival (PFS) — 11.3; 8.9 Weeks
Diabetes Mellitus, Type 2
Primary: Percentage of Patients Reaching the Endpoint: Progression to Diabetes - Valsartan Versus Non-valsartan — 33.1; 36.8 Percentage of patients
Advanced Breast Cancer
Primary: Number of Patients With a Disease Progression Event — 24; 18 Participants
Colorectal · Cancer
Primary: Number of Patients With an Objective Disease Progression Event — 23; 27; 24 Participants
Non-small Cell Lung Cancer · Lung Cancer
Primary: Progression-Free Survival (PFS) in the Overall Population — 17.3; 14 Weeks
Renal Transplantation
Primary: Renal Function (Nankivell Formula) at Month 12 Post Transplantation. — 71.84; 61.24 mL/min /1.73m^2
Essential Hypertension
Primary: Change in Mean Sitting Diastolic Blood Pressure (MSDBP) From Baseline to Week 8 Endpoint — -10.3; -6.6 mmHg